Group 1 - The core point of the article is that Zhendong Pharmaceutical announced a board meeting to discuss providing guarantees for its wholly-owned subsidiary [1] - For the first half of 2025, Zhendong Pharmaceutical's revenue composition includes: pharmaceutical production and sales accounting for 110.27%, medicinal herb planting at 31.67%, and technical services at 3.38%, with inter-segment eliminations at -45.32% [1] - As of the report, Zhendong Pharmaceutical has a market capitalization of 6.9 billion yuan [1]

Group 1 - The company, Zhendong Pharmaceutical, announced a share buyback of approximately 13.02 million shares, representing 1.29% of its total share capital, with a total expenditure of about 52.03 million RMB [1] - The highest and lowest prices for the share buyback were 10.06 RMB and 3.51 RMB per share, respectively [1] - As of the report date, the market capitalization of Zhendong Pharmaceutical is 8.6 billion RMB [1] Group 2 - For the first half of 2025, the revenue composition of Zhendong Pharmaceutical is as follows: pharmaceutical production and sales accounted for 110.27%, herbal planting industry for 31.67%, and technical services for 3.38%, with inter-segment eliminations at -45.32% [1]